Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

Anti CD66 Trial

Trial Name

Anti-CD66 - A randomised Phase II Clinical Trial using Targeted Radiotherapy delivered by an Yttrium-90 Radio-labelled Anti-CD66 Monoclonal Antibody with high dose melphalan compared to melphalan alone, prior to Autologous Stem Cell Transplantation for Multiple Myeloma. 

Description

A randomised phase II trial comparing two transplant conditioning schedules prior to autologous stem cell transplantation in patients with multiple myeloma.

Objectives

Primary Objective:

Secondary Ojective:

Design

A randomised, non-blind Phase II study with two treatment arms comparing two transplant conditioning schedules prior to autologous stem cell rescue:

Status

Complete

Population

80 Patients with multiple myeloma scheduled for autologous stem cell transplantation recruited from three treatment centres and randomised in a 1:1 fashion.

Contact details

All Trial enquiries should be addressed to ctu@soton.ac.uk

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×